- Home
- URGN vs CTV Comparison
URGN vs CTV Comparison
Compare URGN & CTV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- URGN
- CTV
- Stock Information
- Founded
- URGN 2004
- CTV 2007
- Country
- URGN United States
- CTV United States
- Employees
- URGN N/A
- CTV N/A
- Industry
- URGN Biotechnology: Pharmaceutical Preparations
- CTV Advertising
- Sector
- URGN Health Care
- CTV Consumer Discretionary
- Exchange
- URGN Nasdaq
- CTV Nasdaq
- Market Cap
- URGN 465.9M
- CTV 450.1M
- IPO Year
- URGN 2017
- CTV N/A
- Fundamental
- Price
- URGN $10.27
- CTV $3.08
- Analyst Decision
- URGN Strong Buy
- CTV Hold
- Analyst Count
- URGN 5
- CTV 3
- Target Price
- URGN $44.50
- CTV $2.83
- AVG Volume (30 Days)
- URGN 487.3K
- CTV 2.1M
- Earning Date
- URGN 03-13-2025
- CTV 02-25-2025
- Dividend Yield
- URGN N/A
- CTV N/A
- EPS Growth
- URGN N/A
- CTV N/A
- EPS
- URGN N/A
- CTV N/A
- Revenue
- URGN $89,363,000.00
- CTV $151,557,000.00
- Revenue This Year
- URGN $13.39
- CTV $9.64
- Revenue Next Year
- URGN $45.06
- CTV $10.07
- P/E Ratio
- URGN N/A
- CTV N/A
- Revenue Growth
- URGN 15.64
- CTV 12.30
- 52 Week Low
- URGN $9.78
- CTV $1.25
- 52 Week High
- URGN $20.70
- CTV $3.40
- Technical
- Relative Strength Index (RSI)
- URGN 39.53
- CTV 63.17
- Support Level
- URGN $10.12
- CTV $3.00
- Resistance Level
- URGN $10.96
- CTV $3.08
- Average True Range (ATR)
- URGN 0.57
- CTV 0.03
- MACD
- URGN -0.01
- CTV -0.02
- Stochastic Oscillator
- URGN 24.75
- CTV 72.73
About URGN UroGen Pharma Ltd.
UroGen Pharma Ltd is a clinical-stage biotechnology firm specializing in innovative solutions for urothelial and specialty cancers. The company has developed RTGel reverse-thermal hydrogel, a proprietary technology enhancing the therapeutic profiles of existing drugs by enabling sustained release. Their flagship product, Jelmyto (mitomycin) for pyelocalyceal solution, along with investigational candidate UGN-102 (mitomycin) for intravesical solution, targets non-surgical tumor ablation in forms of non-muscle invasive urothelial cancer. Additionally, their immuno-uro-oncology pipeline includes UGN-301 (zalifrelimab), an anti-CTLA-4 antibody, intended for both monotherapy and combination therapy. Revenue is generated from product sales.
About CTV Innovid Corp.
Innovid Corp is a software platform that provides ad serving, measurement and optimization creative services for the creation, delivery, and measurement of TV ads across connected TV, mobile TV and desktop TV environments to advertisers, publishers and media agencies. It is engaged in ad serving, measurement and creative services. It operates in U.S., Canada, EMEA, APAC and LATAM, out of which it derives maximum revenue from U.S.